Tools
Tools
JAMESON, Adam, FYLAN, Beth, BRISTOW, Greg C., SAGOO, Gurdeep S., DALTON, Caroline, CARDNO, Alastair, SOHAL, Jaspreet and MCLEAN, Samantha L. (2021). What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings? Frontiers in Genetics, 12.
|
PDF
fgene-12-740216.pdf - Published Version Creative Commons Attribution. Download (687kB) | Preview |
|
|
PDF (Supplementary Appendix 1 | PRISMA searching tool flow diagram.)
Table_2.pdf - Supplemental Material Creative Commons Attribution. Download (123kB) | Preview |
|
|
PDF (Supplementary Appendix 2 | Table of included studies and their characteristics.)
Table_1.pdf - Supplemental Material Creative Commons Attribution. Download (157kB) | Preview |
Abstract
In psychiatry, the selection of antipsychotics and antidepressants is generally led by a trial-and-error approach. The prescribing of these medications is complicated by sub-optimal efficacy and high rates of adverse drug reactions (ADRs). These both contribute to poor levels of adherence. Pharmacogenetics (PGx) considers how genetic variation can influence an individual’s response to a drug. Pharmacogenetic testing is a tool that could aid clinicians when selecting psychotropic medications, as part of a more personalized approach to prescribing. This may improve the use of and adherence to these medications. Yet to date, the implementation of PGx in mental health environments in the United Kingdom has been slow. This review aims to identify the current barriers and enablers to the implementation of PGx in psychiatry and determine how this can be applied to the uptake of PGx by NHS mental health providers. A systematic searching strategy was developed, and searches were carried out on the PsychInfo, EmBase, and PubMed databases, yielding 11 appropriate papers. Common barriers to the implementation of PGx included cost, concerns over incorporation into current workflow and a lack of knowledge about PGx; whilst frequent enablers included optimism that PGx could lead to precision medicine, reduce ADRs and become a more routine part of psychiatric clinical care. The uptake of PGx in psychiatric care settings in the NHS should consider and overcome these barriers, while looking to capitalize on the enablers identified in this review.
| Item Type: | Article |
|---|---|
| Additional Information: | ** From Frontiers via Jisc Publications Router ** Licence for this article: http://creativecommons.org/licenses/by/4.0/ **Journal IDs: eissn 1664-8021 **History: published_online 22-09-2021; accepted 30-08-2021; submitted 12-07-2021; collection 2021 |
| Uncontrolled Keywords: | Genetics, pharmacogenomics, pharmacogenetics, pharmacogenetic testing, psychiatry, mental health |
| Identification Number: | https://doi.org/10.3389/fgene.2021.740216 |
| SWORD Depositor: | Colin Knott |
| Depositing User: | Colin Knott |
| Date Deposited: | 06 Oct 2021 09:51 |
| Last Modified: | 06 Oct 2021 10:00 |
| URI: | https://shura.shu.ac.uk/id/eprint/29132 |
Actions (login required)
 |
View Item |
Downloads
Downloads per month over past year